WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003062472) COOPERATIVE OLIGONUCLEOTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/062472    International Application No.:    PCT/US2003/001814
Publication Date: 31.07.2003 International Filing Date: 22.01.2003
IPC:
A61K 38/00 (2006.01), C12N 15/10 (2006.01), C12N 15/11 (2006.01)
Applicants: HYBRIDON, INC. [US/US]; 345 Vassar Street, Cambridge, MA 02139 (US) (For All Designated States Except US).
KANDIMALLA, Ekambar, M. [IN/US]; (US) (For US Only).
AGRAWAL, Sudhir [US/US]; (US) (For US Only)
Inventors: KANDIMALLA, Ekambar, M.; (US).
AGRAWAL, Sudhir; (US)
Agent: KERNER, Ann-Louise, Ph.D.; Hale and Dorr LLP, 60 State Street, Boston, MA 02109 (US)
Priority Data:
10/054,429 22.01.2002 US
Title (EN) COOPERATIVE OLIGONUCLEOTIDES
(FR) OLIGONUCLEOTIDES COOPERATIFS
Abstract: front page image
(EN)Disclosed is a composition comprising at least two synthetic, cooperative oligonucleotides, each comprising a region complementary to one of tandem, non−overlapping regions of a target single−stranded nucleic acid, and each further comprising a non−nucleotidic binding partner at a terminus of each of the oligonucleotides, such that the binding partners can interact with each other to form a stable complex. Also disclosed are dimeric structures, ternary complexes, pharmaceutical formulations, and methods utilizing the cooperative oligonucleotides of the invention.
(FR)L'invention concerne une composition comprenant au moins deux oligonucléotides coopératifs synthétiques, comprenant respectivement une région complémentaire à une des régions tandem non-chevauchantes d'un acide nucléique monocaténaire cible, et comprenant également respectivement un partenaire de liaison non-nucléotidique à une extrémité de chaque oligonucléotide, de telle façon que les partenaires de liaison puissent interagir les uns avec les autres pour former un complexe stable. L'invention concerne également des structures dimériques, des complexes centraux, des formulations pharmaceutiques et des procédés utilisant les oligonucléotides coopératifs de l'invention.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)